25 results about "Nociception" patented technology

Method, device, system and associated processing logic for providing optimal perioperative nociception management to anesthetized patient, including monitoring a plurality of nociception-related physiological parameters of the patient using at least two non-invasive physiological sensors; combining the plurality of nociception-related physiological parameters into a nociception index value indicative of a level of nociception of the patient, by applying a machine learning algorithm on the plurality of nociception-related physiological parameters and / or features derived therefrom; comparing the nociception index value to a first threshold value indicative of an upper limit of nociceptive-anti-nociceptive balance (NANB) and to a second threshold value indicative of a lower limit of NANB; and providing a treatment or treatment recommendation based on the comparison and on a clinical concern.

The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and / or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling.

The present invention relates to a process for production of nerve growth factor (NGF) and muteins thereof, in particular muteins of human NGF. The process of the present invention yields nerve growth factor (NGF) and muteins thereof, e.g. from recombinant sources, at high purity. Aspects related to the process of the present invention, such as muteins obtainable thereby, are also described. The respective muteins may be characterized e.g. by improved detectability and / or reduced nociceptive activity, compared to wildtype human NGF.

The present disclosure provides compositions and methods for treating and preventing localized nociception, inflammation, or morphological changes associated with joint disease or illness, back or spine conditions or disorders, and musculoskeletal diseases or dysfunction.

Photobiomodulation (PBM) can be delivered to small fibers within a target nerve before, during, and / or after surgery (using a surgical tool and a controller) to silence small fibers within the target nerve to treat one or more neurological disorders (e.g., nociceptive pain). By silencing small fibers conveying nociceptive information, acute nociceptive pain can be dulled and chronification of acute nociceptive pain can be slowed, halted, and / or prevented. The surgical tool includes an optical emitter, a body configured to hold the optical emitter, and a shield coupled to and / or incorporated into the body. The body can direct a dose of PBM to a target through a surgical opening. The shield can be positioned to extend outward from the body and to contain at least a portion of excess light of the dose of PBM. The controller can set the dose of PBM at an amount for a time.

The present invention relates to a synergistic composition for controlling headache disorders. The composition comprises Palmitoylethanolamide, Magnesium, and Ginkgolide B, along with pharmaceutically acceptable excipients. The invention addresses primary headache disorders, including migraine and tension-type headaches, which represent the majority of headache disorders. Palmitoylethanolamide exhibits analgesic and anti-inflammatory properties, down¬ regulating pro-inflammatory and nociceptive pathways. Magnesium contributes to the reduction of headache symptoms, while Ginkgolide B, derived from Ginkgo biloba, enhances the therapeutic effect. Animal studies have demonstrated the synergistic efficacy of this combination in reducing the frequency, duration, and severity of headache symptoms, both independently and when used with standard treatments.

The present invention relates to a process for production of nerve growth factor (NGF) and muteins thereof, in particular muteins of human NGF. The process of the present invention yields nerve growth factor (NGF) and muteins thereof, e.g. from recombinant sources, at high purity. Aspects related to the process of the present invention, such as muteins obtainable thereby, are also described. The respective muteins may be characterized e.g. by improved detectability and / or reduced nociceptive activity, compared to wildtype human NGF.

A hemodynamic monitoring system monitors a patient's arterial pressure and provides an alert to a medical professional of the patient's nociception. The system includes a hemodynamic sensor that generates hemodynamic data representative of the patient's arterial pressure waveform. A hardware processor of the system is configured to execute nociception detection software code to perform waveform analysis of the hemodynamic data to determine a plurality of signal measurements. Detection input features indicative of a nociceptive event in the patient are extracted by the processor from the plurality of signal measurements. A nociceptive score representative of a probability of a nociceptive event in the patient is determined from the detection input features. A sensory alarm is activated in response to the nociceptive score meeting a predetermined detection criterion.

Described herein are methods and systems for predicting a post-operative condition that may be experienced by a patient, following a surgical procedure. In one or more embodiments, a method for quantifying a patient response to surgery comprises generating a single index that quantifies a patient condition of a patient using a nociception response of the patient during a surgical procedure, where the nociception response includes a hemodynamic response of the patient detected within a non-fixed length, continuously increasing window of time that increases until conclusion of the surgical procedure.

Systems and methods for patient monitoring and / or treatment are provided. The system may include one or more sensors configured to measure electroencephalogram (EEG) signals and electrodermal characteristic signals of a patient administered at least one anesthetic agent and at least one analgesic agent during a medical surgical procedure. The system may further include a processor operatively coupled to the one or more sensors. The processor receives the EEG signals and the electrodermal characteristic signals and uses the EEG signals or the electrodermal characteristic signals to generate a report indicative of a nociceptive state of the patient in real time during the medical surgical procedure while the patient is administered the at least one anesthetic agent and is administered a pain management plan based on a target post-operative outcome.

This invention relates to the fields of medical data processing and multimodal emotion computing, and discloses an emotion state recognition system for vocal micro-expressions in patients with advanced cancer. The system constructs a temporal state vector reflecting the patient's neural control ability by calculating the neural conduction lag rate and the physiological vocal energy index. A state-adaptive gating module generates a confidence mask to weight the multimodal features. Subsequently, an emotion decoupling and reconstruction module uses manifold orthogonal projection to separate the weighted features into physiological harm perception components and psychological emotional response components, and combines sparse dictionary reconstruction to remove noise. Finally, a fusion decision and grading module combines a temporal convolutional network with an adaptive threshold calibration mechanism based on the energy index to output pain grading results and decision signals. This invention can effectively distinguish between a patient's subjective masking and physiological exhaustion state, decouple the physical and psychological attributes of pain, and avoid missed detections due to weak reactions.

The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and / or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling.

A pituitary adenylate cyclase activating peptide (PACAP) is a neuropeptide associated with a broad range of functions such as nociceptive feelings and primary headache. PACAP is a member of the trypsin / vasoactive intestinal peptide (VIP) / growth hormone releasing hormone (GHRH) family. The present disclosure relates generally to anti-PACAP antibodies, pharmaceutical compositions comprising such antibodies, and methods of producing and using such antibodies.

The invention provides hydrochloride hydrate solid forms of the compound MCOPPB (i.e., (R)-1-(1-(1-methylcyclooctyl)piperidin-4-yl)-2-(piperidin-3-yl)-1H-benzo[d]imidazole), pharmaceutical compositions thereof, methods for preparing the same, and their use in agonizing the NOP receptor (i.e., the nociceptin / orphanin FQ receptor) and treating a disease or condition mediated by a NOP receptor, such as pain.

Systems and methods are provided for patient monitoring and / or treatment. The system may include one or more sensors configured to measure electroencephalogram (EEG) and electrodermal signals of a patient subject to at least one anesthetic agent and at least one analgesic agent during an operative medical procedure. The system can also include a processor, operably coupled to the one or more sensors. The processor is configured to receive the EEG and electrodermal signals and, using the EEG or electrodermal signals, generate a report indicating the nociceptive state of the patient in real-time during the operative medical procedure while the patient is subject to the at least one anesthetic and a pain management plan based on desired post-operative outcomes.

Systems and methods are provided for patient monitoring and / or treatment. The system may include one or more sensors configured to measure electroencephalogram (EEG) and electrodermal signals of a patient subject to at least one anesthetic agent and at least one analgesic agent during an operative medical procedure. The system can also include a processor, operably coupled to the one or more sensors. The processor is configured to receive the EEG and electrodermal signals and, using the EEG or electrodermal signals, generate a report indicating the nociceptive state of the patient in real-time during the operative medical procedure while the patient is subject to the at least one anesthetic and a pain management plan based on desired post-operative outcomes..

Substituted cyclohexyl chemical entities of Formula (I):wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.

The present invention provides: a biomarker for identifying nociceptive pain and nociplastic pain; a biomarker for determining therapeutic effects on nociceptive pain and nociplastic pain; an examination method for nociceptive pain and nociplastic pain, using the biomarkers; a method for evaluating the severity in a patient with nociceptive pain and a patient with nociplastic pain; a method for determining therapeutic effects on nociceptive pain and nociplastic pain; and a kit including a reagent for measuring the amounts of the biomarkers.

Method, device, system and associated processing logic for providing optimal perioperative nociception management to anesthetized patient, including monitoring a plurality of nociception-related physiological parameters of the patient using at least two non-invasive physiological sensors; combining the plurality of nociception-related physiological parameters into a nociception index value indicative of a level of nociception of the patient, by applying a machine learning algorithm on the plurality of nociception-related physiological parameters and / or features derived therefrom; comparing the nociception index value to a first threshold value indicative of an upper limit of nociceptive-anti-nociceptive balance (NANB) and to a second threshold value indicative of a lower limit of NANB; and providing a treatment or treatment recommendation based on the comparison and on a clinical concern.

The present disclosure provides compositions and methods for treating and preventing localized nociception, inflammation, or morphological changes associated with joint disease or illness, back or spine conditions or disorders, and musculoskeletal diseases or dysfunction with an LNP-encapsulated CRISPR / Cas9 gene editing system.

In some examples, a patient monitoring system includes processing circuitry configured to detect an occurrence of a nociception event of a patient during a medical procedure. The processing circuitry may, for example, determine, based at least in part on a nociception parameter of the patient in an interrogation window, a nociception parameter level, determine, based at least in part on the nociception parameter of the patient in a baseline window that corresponds to the interrogation window, a baseline nociception parameter level, determine a difference in nociception parameter levels between the baseline nociception parameter level and the nociception parameter level, detect, based at least in part on the difference in nociception parameter levels, an occurrence of a nociception event, and in response to detecting the occurrence of the nociception event, provide an indication to adjust an amount of analgesic administered to the patient.